Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13133071 | 0.87 | TSHR (0.46) | TSHRALDH1A1CYP4F2CYP4A11LMNA | |
| SCHEMBL19500081 | 0.86 | TSHR (0.37) | TSHRALDH1A1CYP4F2CYP4A11ACHE | |
| SCHEMBL18669142 | 0.85 | ACHE (0.41) | TSHRALDH1A1CYP4F2CYP4A11ACHE | |
| SCHEMBL29728727 | 0.84 | TSHR (0.39) | TSHRALDH1A1CYP4F2CYP4A11LMNA | |
| SCHEMBL14715673 | 0.83 | TSHR (0.42) | TSHRALDH1A1LMNAHCAR2 | |
| SCHEMBL19176967 | 0.82 | TSHR (0.35) | TSHRALDH1A1ACHECHRNB2CHRNB4 | |
| SCHEMBL11229306 | 0.82 | TSHR (0.35) | TSHRALDH1A1ACHECHRNB2CHRNB4 | |
| SCHEMBL13133088 | 0.81 | TSHR (0.40) | TSHRALDH1A1CYP4F2CYP4A11LMNA | |
| SCHEMBL577735 | 0.81 | LMNA (0.42) | TSHRALDH1A1LMNAHCAR2 | |
| SCHEMBL2695801 | 0.81 | TSHR (0.40) | TSHRALDH1A1LMNAHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | claimed |
| CN-105646637-B | A kind of abiraterone derivative and preparation method thereof and medical usage | 四川海思科制药有限公司 | 2018-12-14 | — | — | CN | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| CN-107382870-A | N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine | 四川海思科制药有限公司 | 2017-11-24 | — | — | CN | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| CN-106536505-A | Dabigatran etexilate derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-105646637-A | Abiraterone derivative, preparation method and medical applications thereof | 四川海思科制药有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-9296681-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2016019849-A1 | DABIGATRAN CARBOALKOXY DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2016-02-11 | — | — | WO | disclosed |
| WO-2016019849-A1 | DABIGATRAN CARBOALKOXY DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2016-02-11 | — | — | WO | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8604244-B2 | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012003501-A2 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| EP-0468643-A1 | Process for the preparation of acrylates | THE BRITISH PETROLEUM COMPANY P.L.C. (GB) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | PNMT, TPH1, TPH2 | TSHR 2441/4885ALDH1A1 407/4885CYP4F2 1614/4885 |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | TSHR 4224/4885ALDH1A1 2012/4885CYP4F2 3866/4885 |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | TPH1, TPH2, PNMT | TSHR 3227/4885ALDH1A1 610/4885CYP4F2 1415/4885 |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, TPH1, TPH2 | TSHR 2539/4885ALDH1A1 463/4885CYP4F2 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.